<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/58">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/58">
<title>RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial</title>
<dc:title>RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial</dc:title>
<dc:creator>Burbach, JP M</dc:creator>
<dc:creator>Verkooijen, Helena M</dc:creator>
<dc:creator>Intven, Martijn</dc:creator>
<dc:creator>Kleijnen, Jean-Paul JE</dc:creator>
<dc:creator>Bosman, Mirjam E</dc:creator>
<dc:creator>Raaymakers, Bas W</dc:creator>
<dc:creator>van Grevenstein, Wilhelmina MU</dc:creator>
<dc:creator>Koopman, Miriam</dc:creator>
<dc:creator>Seravalli, Enrica</dc:creator>
<dc:creator>van Asselen, Bram</dc:creator>
<dc:creator>Reerink, Onne</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-015-0586-4</dc:identifier>
<dc:source>Trials 2015, 16:58</dc:source>
<dc:date>2015-02-22</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-02-22</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>58</prism:startingPage>
<prism:copyright>2015 Burbach et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="JP M Burbach" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Helena M Verkooijen" />
<meta name="citation_author_institution" content="Trial Bureau Imaging Division, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Martijn Intven" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Jean-Paul JE Kleijnen" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Mirjam E Bosman" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Bas W Raaymakers" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Wilhelmina MU van Grevenstein" />
<meta name="citation_author_institution" content="Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Miriam Koopman" />
<meta name="citation_author_institution" content="Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Enrica Seravalli" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Bram van Asselen" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />
<meta name="citation_author" content="Onne Reerink" />
<meta name="citation_author_institution" content="Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-02-22" />
<meta name="citation_firstpage" content="58" />
<meta name="citation_doi" content="10.1186/s13063-015-0586-4" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-015-0586-4.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-015-0586-4.pdf" />
<meta name="title" content="RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial" />
<meta name="description" content="Treatment for locally advanced rectal cancer (LARC) consists of chemoradiation therapy (CRT) and surgery. Approximately 15% of patients show a pathological complete response (pCR). Increased pCR-rates can be achieved through dose escalation, thereby increasing the number patients eligible for organ-preservation to improve quality of life (QoL). A randomized comparison of 65 versus 50Gy with external-beam radiation alone has not yet been performed. This trial investigates pCR rate, clinical response, toxicity, QoL and (disease-free) survival in LARC patients treated with 65Gy (boost + chemoradiation) compared with 50Gy standard chemoradiation (sCRT)." />

<meta name="dc.title" content="RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial" />
<meta name="dc.creator" content="Burbach, JP M" />
<meta name="dc.creator" content="Verkooijen, Helena M" />
<meta name="dc.creator" content="Intven, Martijn" />
<meta name="dc.creator" content="Kleijnen, Jean-Paul JE" />
<meta name="dc.creator" content="Bosman, Mirjam E" />
<meta name="dc.creator" content="Raaymakers, Bas W" />
<meta name="dc.creator" content="van Grevenstein, Wilhelmina MU" />
<meta name="dc.creator" content="Koopman, Miriam" />
<meta name="dc.creator" content="Seravalli, Enrica" />
<meta name="dc.creator" content="van Asselen, Bram" />
<meta name="dc.creator" content="Reerink, Onne" />
<meta name="dc.description" content="Treatment for locally advanced rectal cancer (LARC) consists of chemoradiation therapy (CRT) and surgery. Approximately 15% of patients show a pathological complete response (pCR). Increased pCR-rates can be achieved through dose escalation, thereby increasing the number patients eligible for organ-preservation to improve quality of life (QoL). A randomized comparison of 65 versus 50Gy with external-beam radiation alone has not yet been performed. This trial investigates pCR rate, clinical response, toxicity, QoL and (disease-free) survival in LARC patients treated with 65Gy (boost + chemoradiation) compared with 50Gy standard chemoradiation (sCRT)." />
<meta name="dc.source" content="Trials 2015 16:58" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-02-22" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-015-0586-4" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Burbach et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-02-22" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="58" />
<meta name="prism.copyright" content="2015 Burbach et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/58/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/58" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-015-0586-4.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-015-0586-4-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/015/0586/4";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/015/0586/4</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0586/4/11165129788@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0586/4/12539783633@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/pdf/s13063-015-0586-4.pdf">PDF</a>
			<span>(1.9MB)</span>
		</li>

        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.trialsjournal.com/content/16/1/58/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22RandomizEd+controlled+trial+for+pre-operAtive+dose-escaLation+BOOST+in+locally+advanced+rectal+cancer+%28RECTAL+BOOST+study%29%3A+study+protocol+for+a+randomized+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22JPM+Burbach%22">Burbach JPM</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22HM+Verkooijen%22">Verkooijen HM</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Intven%22">Intven M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22JPJE+Kleijnen%22">Kleijnen JPJE</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22ME+Bosman%22">Bosman ME</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22BW+Raaymakers%22">Raaymakers BW</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22WMU+van Grevenstein%22">van Grevenstein WMU</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Koopman%22">Koopman M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22E+Seravalli%22">Seravalli E</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22B+van Asselen%22">van Asselen B</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22O+Reerink%22">Reerink O</a>
            </li>
            </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/58">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/58">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/download/xml/s13063-015-0586-4.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-015-0586-4&volume=16&issue=1&title=RandomizEd+controlled+trial+for+pre-operAtive+dose-escaLation+BOOST+in+locally+advanced+rectal+cancer+%28RECTAL+BOOST+study%29%3A+study+protocol+for+a+randomized+controlled+trial&author_name=JP Maarten Burbach&start_page=1&end_page=8">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F58" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/58', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/58" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/58', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F58" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/58', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/58" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/58', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/58', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/58" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/58" data-counturl="http://www.trialsjournal.com/content/16/1/58" data-hashtags="trials
" data-text="RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/58', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial http://www.trialsjournal.com/content/16/1/58"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/58"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0ARandomizEd%20controlled%20trial%20for%20pre-operAtive%20dose-escaLation%20BOOST%20in%20locally%20advanced%20rectal%20cancer%20%28RECTAL%20BOOST%20study%29%3A%20study%20protocol%20for%20a%20randomized%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F58&title=RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/58&title=RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="/content/16/1/58/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/58"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/58"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/58', 1, true]);" href="http://twitter.com/?status=RandomizEd%20controlled%20trial%20for%20pre-operAtive%20dose-escaLation%20BOOST%20in%20locally%20advanced%20rectal%20cancer%20%28RECTAL%20BOOST%20study%29%3A%20study%20protocol%20for%20a%20randomized%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F58+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/58'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0586/4/17461132946@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0586/4/16217213654@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																         <strong>JP Maarten Burbach</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup><sup>&#42;</sup>, <strong>Helena M Verkooijen</strong><sup><a href="/content/16/1/58/#ins2">2</a></sup>, <strong>Martijn Intven</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>, <strong>Jean-Paul JE Kleijnen</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>, <strong>Mirjam E Bosman</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>, <strong>Bas W Raaymakers</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>, <strong>Wilhelmina MU van Grevenstein</strong><sup><a href="/content/16/1/58/#ins3">3</a></sup>, <strong>Miriam Koopman</strong><sup><a href="/content/16/1/58/#ins4">4</a></sup>, <strong>Enrica Seravalli</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>, <strong>Bram van Asselen</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup> and <strong>Onne Reerink</strong><sup><a href="/content/16/1/58/#ins1">1</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            JP M Burbach <a href='mailto:j.p.m.burbach-2@umcutrecht.nl'>j.p.m.burbach-2@umcutrecht.nl</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Department of Radiation Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Trial Bureau Imaging Division, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584, CX, The Netherlands
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:58&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-015-0586-4</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/58">http://www.trialsjournal.com/content/16/1/58</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>29 September 2014</td></tr>                <tr><td>Accepted:</td><td>30 January 2015</td></tr>        <tr><td>Published:</td><td>22 February 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Burbach et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Treatment for locally advanced rectal cancer (LARC) consists of chemoradiation therapy
         (CRT) and surgery. Approximately 15% of patients show a pathological complete response
         (pCR). Increased pCR-rates can be achieved through dose escalation, thereby increasing
         the number patients eligible for organ-preservation to improve quality of life (QoL).
         A randomized comparison of 65 versus 50Gy with external-beam radiation alone has not
         yet been performed. This trial investigates pCR rate, clinical response, toxicity,
         QoL and (disease-free) survival in LARC patients treated with 65Gy (boost + chemoradiation)
         compared with 50Gy standard chemoradiation (sCRT).
      </p>
      <h4>Methods/design</h4>
      <p style="line-height:160%">This study follows the ‘cohort multiple randomized controlled trial’ (cmRCT) design:
         rectal cancer patients are included in a prospective cohort that registers clinical
         baseline, follow-up, survival and QoL data. At enrollment, patients are asked consent
         to offer them experimental interventions in the future. Eligible patients—histologically
         confirmed LARC (T3NxM0 &lt;1 mm from mesorectal fascia, T4NxM0 or TxN2M0) located ≤10
         cm from the anorectal transition who provided consent for  experimental intervention
         offers—form a subcohort (<em>n</em> = 120). From this subcohort, a random sample is offered the boost prior to sCRT (<em>n</em> = 60), which they may accept or refuse. Informed consent is signed only after acceptance
         of the boost. Non-selected patients in the subcohort (<em>n</em> = 60) undergo sCRT alone and are not notified that they participate in the control
         arm until the trial is completed.
      </p>
      <p style="line-height:160%">sCRT consists of 50Gy (25 × 2Gy) with concomitant capecitabine. The boost (without
         chemotherapy) is given prior to sCRT and consists of 15 Gy (5 × 3Gy) delivered to
         the gross tumor volume (GTV). The primary endpoint is pCR (TRG 1). Secondary endpoints
         include acute grade 3–4 toxicity, good pathologic response (TRG 1-2), clinical response,
         surgical complications, QoL and (disease-free) survival. Data is analyzed by intention
         to treat.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">The boost is delivered prior to sCRT so that GTV adjustment for tumor shrinkage during
         sCRT is not necessary. Small margins also aim to limit irradiation of healthy tissue.
         The cmRCT design provides opportunity to overcome common shortcomings of classic RCTs,
         such as slow recruitment, disappointment-bias in control arm patients and poor generalizability.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">The Netherlands Trials Register NL46051.041.13. Registered 22 August 2013. ClinicalTrials.gov
         <a href="NCT01951521">NCT01951521</a> <a href="http://www.webcitation.org/query.php?url=NCT01951521&amp;refdoi=10.1186/s13063-015-0586-4" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>. Registered 18 September 2013.
      </p>
   </div>
</section>
<section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Colorectal cancer is the second most common cancer in women and third in men worldwide
         <a name="d79560e234"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. Almost one-third of Dutch colorectal cancers are located in the rectum <a name="d79560e238"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]. Rectal cancers are treated by surgery, preceded by chemoradiation in case of locally
         advanced rectal cancer (LARC). Chemoradiation consists of a total dose of about 50&nbsp;Gy
         combined with capecitabine. With this treatment regimen, approximately 15% of patients
         show a pathological complete response (pCR) <a name="d79560e242"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>],<a name="d79560e246"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>], classified by Mandard <em>et al</em>. as tumor regression grade 1 (TRG 1) <a name="d79560e254"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>]. In a recent meta-analysis, we showed that doses of ≥60&nbsp;Gy were associated with an
         increased pCR rate to 20.4%, without compromising toxicity <a name="d79560e258"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>].
      </p>
      <p style="line-height:160%">Patients with ‘good’ clinical response, either pCR (TRG 1) or near-pCR (TRG 2), might
         be eligible for organ-preserving approaches. The aim of these strategies is to deliver
         an optimal quality of life (QoL) without compromising the oncologic outcome in this
         favorable subgroup. Recently, several protocols have been developed, that use either
         local excision <a name="d79560e264"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>]-<a name="d79560e268"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>] or a “watch-and-wait” policy <a name="d79560e272"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]-<a name="d79560e276"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>], in order to omit surgery (total mesorectal excision) as the primary treatment. In
         addition, patients who reach a pCR often show reduced local recurrence and improved
         (disease-free) survival probabilities compared with patients with a poor response
         (TRG 3–5) <a name="d79560e280"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>],<a name="d79560e285"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]-<a name="d79560e289"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>], possibly driven by a favorable tumor biology.
      </p>
      <p style="line-height:160%">Thus, by escalating the preoperative radiation dose, the amount of patients with a
         ‘good’ clinical response or pCR who are eligible for organ-preserving treatment can
         potentially be increased. However, response rates after high-dose external radiation
         with 65&nbsp;Gy have not yet been investigated in a randomized setting. Therefore, we set
         up an exploratory trial, the RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation
         BOOST in Locally Advanced Rectal Cancer (RECTAL BOOST study: ClinicalTrials.gov NCT01951521)
         to compare tumor pCR rates (TRG 1), pathologic ‘good’ responses, toxicity levels,
         clinical tumor response and QoL between patients treated with 65&nbsp;Gy chemoradiation
         (15&nbsp;Gy boost plus 50&nbsp;Gy chemoradiation) and those treated with 50&nbsp;Gy standard chemoradiation
         therapy (sCRT).
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/design</h3>
   <div class="collapsible-content">
      <h4>Study design</h4>
      <p style="line-height:160%">This study is being conducted within the ProspectIve data CollectioN Initiative on
         Colorectal cancer (PICNIC) project <a name="d79560e305"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. The prospective observational PICNIC cohort includes patients with colorectal cancer
         of all stages. Information collected includes baseline demographic and clinical data,
         as well as prospective clinical follow-up and patient-reported outcome measures (PROMs).
         The study follows the cohort multiple randomized controlled trial (cmRCT) design <a name="d79560e309"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>] and provides a pragmatic infrastructure for multiple randomized controlled trials
         (RCTs).
      </p>
      <h4>Patient recruitment</h4>
      <p style="line-height:160%">At enrollment in the PICNIC cohort, patients are asked to provide informed consent
         for prospective collection of clinical, survival and PROMs data. In addition, according
         to the cmRCT design, we ask patients’ consent to be randomly selected to receive offers
         on experimental interventions in the future and to use their data comparatively within
         the context of the PICNIC project.
      </p>
      <p style="line-height:160%">From among the PICNIC cohort, we will identify all patients eligible for the boost
         intervention based on the following inclusion criteria: (1) histologically confirmed
         LARC, defined as T3 with threatened mesorectal fascia (&lt;1&nbsp;mm), T4 or N2M0 <a name="d79560e321"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>] (based on Dutch guidelines for chemoradiation in rectal cancer <a name="d79560e325"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>], in which N2 is defined as ≥4 positive nodes visible with diameter &gt;9&nbsp;mm or 5 to
         9&nbsp;mm combined with 2 of the following 3 characteristics: irregular border, heterogeneous
         or round-shaped); (2) tumor located ≤10&nbsp;cm from the anorectal transition; and (3)
         previously obtained informed consent to be randomly offered experimental interventions
         within the context of the PICNIC project (Table&nbsp;<a name="d79560e328"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/table/T1">1</a>). Patients are ineligible in case of inflammatory bowel disease, pregnancy, previous
         radiation to the pelvis, contraindication for capecitabine and inadequate comprehension
         of the Dutch language in speech and/or writing. Female patients in whom the tumor
         is located on the anterior wall close to the vagina are also ineligible because the
         maximum tolerated dose to the vagina does not allow for dose escalation when the tumor
         is in proximity to it.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/table/T1"><strong>Table 1.</strong></a> <strong>Inclusion and exclusion criteria for the RECTAL BOOST study</strong><sup><strong>a</strong></sup></div></div>
      <h4>Random selection</h4>
      <p style="line-height:160%">Patients within the PICNIC cohort who meet the above inclusion criteria form a subcohort
         of eligible patients (Figure&nbsp;<a name="d79560e416"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F1">1</a>). From among this subcohort, a random sample is selected on a 1:1 basis with varying
         block sizes (<em>n</em> = 6 to 8) using a centrally available computer program. Randomly selected patients
         are offered the experimental intervention (boost prior to sCRT) by their treating
         physician. If they accept the offer, they will sign an additional informed consent
         to receive the boost. Patients who refuse the boost will receive care as usual (that
         is, sCRT). Patients in the subcohort who will not be randomly selected will not be
         informed about the boost intervention, nor will they be informed about their participation
         in the control arm of this study. When the trial is completed, aggregate disclosure
         about the trial results will be provided to the entire PICNIC cohort at the same time.
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F1"><img align="top" src="/content/figures/s13063-015-0586-4-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>Study design and flowchart.</strong> PICNIC, ProspectIve data CollectioN Initiative on Colorectal cancer; RECTAL BOOST,
         RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation BOOST in Locally Advanced
         Rectal Cancer.
      </div></div>
      <h4>Standard treatment</h4>
      <p style="line-height:160%">sCRT consists of 50&nbsp;Gy (25 × 2&nbsp;Gy on weekdays) combined with capecitabine. The radiation
         dose is delivered by intensity-modulated radiation therapy (IMRT), which is standard
         care in our hospital, to the planned target volume (PTV), which comprises the gross
         tumor volume (GTV) and clinical target volume (CTV). Target volumes are delineated
         on computed tomography (CT) scans, matched to- and combined with T2- and diffusion-weighted
         magnetic resonance imaging (DWI) according to published guidelines <a name="d79560e442"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>]. The CTV follows the mesorectal fascia up to the rectosigmoid curvature and stretches
         maximally to 4&nbsp;cm caudal from the tumor, sparing the sphincter in case of a low anterior
         resection (LAR), or includes the sphincter complex +1-cm margin in case of an abdominoperineal
         resection (APR). The lymph node regions (internal iliac and obturator) stretch from
         the caudal end of the v. iliaca communis downward to the crossing of the internal
         iliac vessels under the m. piriformis, laterally limited by the pelvic muscles. The
         obturator region stretches from the m. obturatorius to the m. levator, ventrally limited
         by the ureter or dorsal side of the neurovascular bundle without inclusion of the
         vesiculae, uterus and vagina. Lateral and dorsal border are marked by the pelvic muscles
         and ventral iliac region. In addition, the presacral region stretches from the upper
         level of the iliac vessels to mesorectum, ventrally limited 2&nbsp;cm from the sacrum,
         including the a. rectalis superior and excluding the neuroforamina. The PTV<sub>CTV50</sub> is a non-uniform margin around the CTV according to local protocol consisting of
         an expansion of 13&nbsp;mm ventrally, 9&nbsp;mm dorsally, 10&nbsp;mm laterally and 10&nbsp;mm craniocaudally
         (Figure&nbsp;<a name="d79560e448"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F2">2</a>). The prescribed dose to the PTV<sub>CTV50</sub> is that 95% of the prescribed dose should cover ≥99% of the PTV. Radiation is delivered
         with an external beam linear accelerator. For position verification, the sCRT protocol
         consists of cone-beam CT prior to the first three fractions and weekly thereafter.
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F2','F2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F2"><img align="top" src="/content/figures/s13063-015-0586-4-2.gif" alt="thumbnail" class="thumbnail"><strong>Figure 2.</strong></a> <strong>Cumulative dose plan of boost plus standard chemoradiation fractions (left) with associated
            dose volume histogram (right).</strong> Delineations of gross tumor volume (GTV) plus planned target volume (PTV<sub>GTV</sub>) (red), clinical target volume (CTV) plus PTV (PTV<sub>CTV</sub>) (green), bladder (brown) and sigmoid (pink). Areas that receive a total dose of
         &gt;65&nbsp;Gy are represented in orange), and those that receive &gt;50&nbsp;Gy are shown in turquoise.
      </div></div>
      <p style="line-height:160%">Capecitabine is administered orally twice daily on treatment days at a dose of 825&nbsp;mg/m<sup>2</sup>, taken 2&nbsp;hours before each radiation fraction and 12&nbsp;hours later. Hematologic toxicity
         is tested every 2&nbsp;weeks. Surgery is performed 10 to 12&nbsp;weeks postradiation according
         to the Dutch guidelines <a name="d79560e479"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. The decision whether to perform total mesorectal excision surgery in form of  LAR
         or APR, is made on the basis of the location and extensiveness of the tumor <a name="d79560e483"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>].
      </p>
      <p style="line-height:160%">Two routine MRI scans are acquired using an MRI protocol developed in house, consisting
         of T2-weighted and DWI image sequences <a name="d79560e489"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>]. The first scan (taken maximally 2&nbsp;weeks prior to radiation) is used for radiation
         planning, and the second (obtained 9&nbsp;weeks postradiation) is used for preoperative
         response evaluation and surgical planning. Immediately prior to surgery, the surgeon
         will also perform a digital rectal examination (DRE)  for clinical response evaluation.
      </p>
      <h4>Boost intervention</h4>
      <p style="line-height:160%">The experimental boost intervention consists of 15&nbsp;Gy (5 × 3&nbsp;Gy on weekdays) to the
         GTV without concomitant chemotherapy. The boost is delivered in the week prior to
         the start of sCRT. A cumulative GTV dose of 65&nbsp;Gy is delivered over the full treatment
         course of 30 fractions (6&nbsp;weeks). This results in an equivalent dose in 2-Gy fractions
         of 66.3&nbsp;Gy (α/β = 10&nbsp;Gy) <a name="d79560e499"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>]. GTV delineation is based on T2-weighted and DWI scans; no CTV<sub>GTV65</sub> margin is applied; and the PTV<sub>GTV65</sub> is defined by a non-uniform margin of +11&nbsp;mm in the anteroposterior direction, +7&nbsp;mm
         in the lateral direction and +13&nbsp;mm in the craniocaudal direction around the GTV,
         which represents tumor movement that was observed on in-house daily MRI scans and
         setup errors <a name="d79560e509"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>]. A volumetric modulated arc therapy stereotactic treatment plan is generated for
         boost patients, whereas IMRT is standard care used in the control arm, that accumulates
         the boost and standard chemoradiation doses (Figure&nbsp;<a name="d79560e512"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F2">2</a>). The maximally allowed cumulative dose within the GTV is 80&nbsp;Gy (123% of 65&nbsp;Gy),
         and the volume receiving 95% of the prescribed dose should be larger than 99% of the
         PTV<sub>GTV65</sub>. The maximum dose around, and dose prescription to, the PTV<sub>CTV50</sub> is similar to the elective sCRT field (that is, 53.5&nbsp;Gy). Daily online cone-beam
         CT scans are used for positioning before each boost fraction, and the sCRT position
         verification protocol follows thereafter.
      </p>
      <p style="line-height:160%">Organs at risk (OARs) consist of the bowel bag (excluding sigmoid), bladder, vagina
         and anal sphincter. The dose constraints for the OARs remain unchanged for boost patients
         (namely, the dose to 1&nbsp;cc of the OARs should be ≤53.5&nbsp;Gy), and the volume receiving
         45&nbsp;Gy is aimed to be less than 195&nbsp;cc for the bowel bag (excluding the sigmoid). OAR
         constraints are leading over PTV<sub>GTV65</sub> coverage and may thus limit GTV dose if necessary. If dose prescriptions cannot be
         reached, a panel of radiation oncologists will discuss the feasibility and anticipated
         safety of the treatment plan and decide either to continue or to adapt the plan toward
         acceptable OAR constraints, taking into account anatomical limitations and planned
         surgery. One additional MRI scan is obtained in patients who receive the boost for
         response prediction purposes at the end of the second week (after ten fractions including
         the five boost fractions) and a rectoscopy for clinical response evaluation is performed
         in a subgroup of boost-arm patients that showed a ‘good’ response based on MRI.
      </p>
      <h4>Primary endpoint</h4>
      <p style="line-height:160%">The primary endpoint of this study is pCR, which is classified according to the Mandard
         classification system as tumor regression grade 1 (TRG 1) <a name="d79560e534"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>] (that is, a sterile specimen with absence of residual cancer cells). Experienced
         gastrointestinal pathologists use a standardized protocol to evaluate the specimens
         <a name="d79560e538"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>], and central review of pathology is performed.
      </p>
      <h4>Secondary endpoints</h4>
      <p style="line-height:160%">Secondary endpoints include non-complete pathologic responses (TRG 2–5), acute grade
         3–4 toxicity, clinical response, surgical complications, QoL and disease-free and
         overall survival. The non-complete pathologic responses are categorized as good (TRG
         1–2) or ‘not good’ (TRG 3–5) by the pathologist. A radiation oncologist will assess
         toxicity at weekly visits during the radiation treatment, as well as 4&nbsp;weeks and 4&nbsp;months
         after completion of sCRT. Toxicity is recorded according to the National Cancer Institute’s
         Common Terminology Criteria for Adverse Events, version 4.03 <a name="d79560e548"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>]. Long-term toxicity, (serious) adverse events (SAEs), hospitalization and other health-related
         problems are registered within the context of the PICNIC cohort during clinical follow-up
         and annual patient-administered questionnaires on health and oncological status. Clinical
         response evaluation is based on MRI (9&nbsp;weeks after completion of chemoradiation; that
         is, the week before surgery) and DRE and rectoscopy, which are both performed right
         before surgery while the patient is under anesthesia. MRI and DRE are standardly performed
         in all patients, whereas rectoscopy is only performed in intervention arm patients
         who showed a good response based on MRI. For the MRI, a combination of T2-weighted
         and DWI sequences is used to measure residual tumor tissue in the initially delineated
         tumor region and its surrounding elective radiation field. Surgical complications
         are registered up to 30&nbsp;days after the primary surgery in all patients and after closure
         of the diverting stoma in patients who previously underwent a LAR. For safety reasons,
         occurrence of anastomotic leakage is monitored closely in the LAR subgroup by daily
         review of postoperative patient charts for 30&nbsp;days. QoL data are recorded by means
         of either online forms (Patient-Reported Outcomes Following Initial treatment and
         Long-term Evaluation of Survivorship (PROFILES): <a href="http://www.profilesregistry.nl/">http://www.profilesregistry.nl/</a> <a href="http://www.webcitation.org/query.php?url=http://www.profilesregistry.nl/&amp;refdoi=10.1186/s13063-015-0586-4" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>) or pencil-and-paper questionnaires. For this purpose, cancer-specific QoL questionnaires
         from the European Organization for Research and Treatment of Cancer (EORTC) are used,
         including the core (QLQ-C30 <a name="d79560e555"></a>[<a onclick="LoadInParent('#B27'); return false;" href="#B27">27</a>]) and colorectal cancer-specific (QLQ-CR29 <a name="d79560e559"></a>[<a onclick="LoadInParent('#B28'); return false;" href="#B28">28</a>],<a name="d79560e563"></a>[<a onclick="LoadInParent('#B29'); return false;" href="#B29">29</a>]) questionnaires. The EORTC QLQ-C30 covers five functional scales, three symptom scales,
         a global QoL scale and six single items. The EORTC QLQ-CR29 assesses urinary, bowel
         and/or stoma, psychological and sexually related QoL issues, as well as side effects
         due to chemotherapy. These questionnaires are provided at the time of diagnosis (baseline)
         and 3, 6, 12, 18 and 24&nbsp;months thereafter. Survival and disease-free survival are
         monitored within the PICNIC project through clinical follow-up records and via a link
         with the Dutch Cancer Registry. Disease-free survival is defined as the time in absence
         of a rectal cancer local recurrence or metastasis.
      </p>
      <h4>Safety</h4>
      <p style="line-height:160%">According to Dutch law, the investigator reports SAEs within 15&nbsp;days following notification
         through a government-based internet portal (Centrale Commissie Mensgebonden Onderzoek
         (Central Committee on Research Involving Human Subjects): <a href="https://www.toetsingonline.nl/">https://www.toetsingonline.nl/</a> <a href="http://www.webcitation.org/query.php?url=https://www.toetsingonline.nl/&amp;refdoi=10.1186/s13063-015-0586-4" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>) to the accredited institutional review board (IRB) that approved the protocol. SAEs
         that result in death or are life-threatening will be reported within 7&nbsp;days.
      </p>
      <p style="line-height:160%">Because this is an exploratory dose escalation study, an independent data and safety
         monitoring board (DSMB) will make recommendations on continuation of the study based
         on safety results, focusing on toxicity and anastomotic leakage. The DSMB consists
         of an expert surgeon, a radiation oncologist and a statistician and is provided, annually
         or after every SAE, with the raw data on the primary and secondary outcomes (including
         toxicity, surgical complications and survival). After the first 10 patients with LAR
         have undergone boost treatment, inclusion of patients scheduled for LAR will be stopped
         for 8&nbsp;months to let the DSMB compare anastomotic leakages between boost and control
         arms. The 8-month period will consist of the time between sCRT to primary surgery
         (10–12 weeks) followed by the time between primary surgery and bowel reconstruction,
         including a postoperative monitoring period (16–20 weeks). Only inclusion of patients
         undergoing LAR will be halted during this stop, because patients undergoing APR have
         no risk of anastomotic leakage, owing to their permanent stoma. The DSMB analyzes
         the data independently of the investigators and reports their advice on continuation
         of the study to the sponsor, which will decide on continuation or stopping of the
         study.
      </p>
      <h4>Sample size considerations</h4>
      <p style="line-height:160%">On the basis of our center’s experience, we assume that 13% of patients will reach
         pCR if undergoing sCRT. On the basis of a prediction model published by Appelt <em>et al.</em><a name="d79560e586"></a>[<a onclick="LoadInParent('#B30'); return false;" href="#B30">30</a>], we expect the pCR rate to be 30% after 65&nbsp;Gy treatment. Because we consider this
         study to constitute preliminary work for subsequent studies aimed at evaluating even
         higher dose increases, we deem it important to find an effect if there really is one,
         but less important to unjustly find an effect. Therefore, we will use a one-sided
         α of 15% because it is unlikely that the pCR rate after boost treatment plus sCRT
         will be lower than after sCRT alone, in combination with a power of 80% because we
         do not want to increase uncertainty when a negative result is achieved. We further
         expect that approximately 80% of the patients who receive a boost offer will accept
         it. Patients who are offered the boost treatment but refuse to undergo the boost will
         remain in the intervention arm for analysis but receive sCRT (Figure&nbsp;<a name="d79560e589"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/58/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/58/figure/F1">1</a>). We expect no cross-over from the control arm to the intervention arm, because only
         patients who are randomly selected to receive a boost offer are informed about and
         offered it, whereas all non-selected patients undergo standard treatment (that is,
         sCRT) without receiving information about the boost trial. Taking into account the
         estimated response rates, together with a 20% refusal rate in the intervention arm,
         we require 60 patients per arm to demonstrate a statistically significant difference.
         We expect to complete recruitment within 3&nbsp;years.
      </p>
      <h4>Data analysis</h4>
      <p style="line-height:160%">Data will be analyzed according to the intention-to-treat principle. Data of eligible
         patients who were randomly offered the boost (intervention arm) will be compared with
         eligible patients who were not randomly selected (control arm). In case of dropout
         (that is, no surgery following chemoradiation), a worst-case analysis will be performed
         in which all non-resected intervention-arm patients are classified as non-complete
         responders and all non-resected control patients are classified as complete responders.
         However, because omission of surgery is not common practice in our institution, we
         expect these numbers to be small. In case of substantial boost treatment refusal in
         the intervention arm, complier average causal effect analysis will be performed to
         deal with differences in compliance with treatment between both arms <a name="d79560e599"></a>[<a onclick="LoadInParent('#B31'); return false;" href="#B31">31</a>]. Outcomes include tumor pCR rate (TRG 1), good pathological response (TRG 1–2), clinical
         response, grade 3–4 toxicity, QoL, recurrence rates and disease-free and overall survival.
      </p>
      <p style="line-height:160%">The primary outcome (proportion of patients with pCR) will be presented in proportions
         and compared by means of the χ<sup>2</sup> test. Toxicity will be presented as the overall and/or time point-specific incidence
         of grade 3–4 toxicity, and differences will be tested with the χ<sup>2</sup> test. QoL will be compared at multiple points in time. A relevant change in the patient’s
         perspective is indicated by a 10% difference or more than 0.5 of the standard deviation
         <a name="d79560e611"></a>[<a onclick="LoadInParent('#B32'); return false;" href="#B32">32</a>]. QoL data will be analyzed by mixed-effects models. Differences in disease-free and
         overall survival rates will be analyzed by Kaplan-Meier analysis and log-rank test.
         Differences with a <em>P</em>-value &lt;0.05 are considered statistically significant, except for the primary endpoint,
         where <em>P</em> &lt; 0.15 has been prespecified.
      </p>
      <h4>Ethical approval</h4>
      <p style="line-height:160%">IRB approval was obtained separately for both the PICNIC project (including the cmRCT
         infrastructure) and the RECTAL BOOST study from the ethical body of the UMC Utrecht
         (under reference numbers 12/510 and 13/522, respectively). The PICNIC project is published
         under NCT02070146 <a name="d79560e628"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>] and the RECTAL BOOST study under NCT01951521 <a name="d79560e632"></a>[<a onclick="LoadInParent('#B33'); return false;" href="#B33">33</a>] on ClinicalTrials.gov.
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The RECTAL BOOST study aims to quantify the effect of an external beam radiation (EBR)
         boost of 15&nbsp;Gy prior to standard chemoradiation (50&nbsp;Gy) on pCR rates in patients with
         locally advanced rectal cancer. Toxicity, clinical (complete) response, (surgical)
         complications, (disease-free) survival, QoL and feasibility of boost delivery are
         secondary endpoints. In this study, we will assess in a randomized fashion whether
         a preoperative 65&nbsp;Gy EBR-only regimen (15&nbsp;Gy boost followed by 50&nbsp;Gy chemoradiation)
         can safely increase the proportion of patients with pCR (TRG 1) in comparison with
         the proportion observed after 50&nbsp;Gy chemoradiation alone. Although contact X-ray <a name="d79560e642"></a>[<a onclick="LoadInParent('#B34'); return false;" href="#B34">34</a>], brachytherapy, EBR and EBR-brachytherapy combined studies <a name="d79560e646"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>] have shown response, sphincter-saving and organ preservation benefits at doses up
         to 60&nbsp;Gy, such benefits have not been shown for the 65&nbsp;Gy dose level when reached
         by an EBR-only approach.
      </p>
      <p style="line-height:160%">High rates of good responders are important, as this will increase the number of patients
         eligible for organ-preserving treatment strategies. These strategies aim to improve
         the QoL of patients with a good response while their good oncologic outcome, and possible
         survival benefits, are maintained. Nevertheless, the value of tumor regression has
         not yet been confirmed as a surrogate endpoint for oncologic outcome in this setting.
         In the present study, however, all patients, including those with a good clinical
         response to preoperative treatment, will still undergo surgery because pathological
         response is the primary endpoint, and because resection remains the standard care
         according to Dutch guidelines <a name="d79560e652"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. Therefore, future randomized studies in patients with good clinical responses after
         (boost) chemoradiation are needed to further assess the effect of radical surgery
         versus organ preservation on QoL, toxicity and (disease-free) survival. In this study,
         we aim to quantify response rate by its current gold standard (that is, pathology),
         which in turn can be correlated to the clinical response data that are also obtained.
         In so doing, this study will provide important insight into the results of dose escalation
         that would otherwise be lacking in a trial that would combine dose escalation and
         omission of surgery within the same trial.
      </p>
      <p style="line-height:160%">In this study, we choose to deliver the boost prior to chemoradiation to obtain maximal
         tumor visibility in order to avoid dose administration to healthy tissue. The rationale
         underlying this is that GTV deformation is likely to occur during sCRT as a result
         of tumor shrinkage, and because the induced inflammatory reaction results in edema
         which hinders adequate GTV definition. Both factors make imaging and delineation of
         the tumor more difficult and less reliable  thereby likely to result in overestimation
         of the remaining GTV. When larger areas would then incorrectly be irradiated, surrounding
         healthy tissue might receive a higher dose than planned. On the basis of our own data
         on patients receiving 5 × 5&nbsp;Gy radiation within one week, we know that tumor shrinkage
         does not yet occur during the first week of radiation, which implies that GTV delineations
         made prior to irradiation remain adequate throughout the first week of (chemo)radiation.
         This allows a single GTV delineation to be used for boost dose planning in the week
         prior to sCRT. Furthermore, we choose to use IMRT because this is the standard of
         care in our hospital, and this study is set up as a single-facility trial. Direct
         applicability of these results should thus be considered when extrapolated to other
         centers in which different radiation techniques are used.
      </p>
      <p style="line-height:160%">We have chosen to apply the cmRCT design, which aims to overcome common shortcomings
         of classic RCTs, such as slow recruitment, disappointment bias in patients randomized
         to the control arm, and poor generalizability. Not uncommonly, oncological patients
         possess strong preferences for experimental treatments that are (often) falsely regarded
         to be superior. This prevents such patients from taking part in randomized studies,
         thereby diminishing recruitment rates for RCTs. Furthermore, patients who remain willing
         to participate in RCTs often represent a younger, healthier, higher-educated subgroup,
         and once participating, these patients are unfortunately often allowed to participate
         in only one trial at a time. All this makes recruitment for RCTs difficult and prone
         to selection bias. Because the cmRCT design uses a cohort as a recruitment pool, it
         represents the routine population more adequately because cohort inclusion is generally
         less selective. Because this baseline may also evolve over time, the cmRCT furthermore
         provides the advantage that the effectiveness of experimental interventions is compared
         with the most up-to-date available standard care with which it should compete, instead
         of competing with outdated treatments which is often the case when classic RCTs are
         published. A new aspect brought by the cmRCT design is that it provides the opportunity
         to evaluate acceptance rates of offered treatments. This offers new insights into
         patient preferences and reasons for refusal of experimental interventions that become
         increasingly important. It forces clinicians and researchers to rethink their treatment
         approach at a much earlier stage when, for instance, a large proportion of patients
         declines the offered treatment. Overall, efficient, less selective recruitment, collection
         of long-term outcomes and early preference monitoring could reduce research costs
         significantly when conducting RCTs within the cmRCT design.
      </p>
      <p style="line-height:160%">The RECTAL BOOST study is a pragmatic RCT performed within the infrastructure of the
         cmRCT design, that aims to quantify the effect on pCR rate of preoperative dose escalation
         to 65&nbsp;Gy in comparison with standard 50&nbsp;Gy chemoradiation in patients with locally
         advanced rectal cancer. If the proportion of good responders can be increased by dose
         escalation, this strategy could provide an option to increase the number of patients
         that may benefit from organ-preserving strategies in the future.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Ethical approval for this trial was obtained in June 2014. Recruitment started in
         September 2014 and is currently ongoing.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">APR: Abdominoperineal resection</p>
      <p style="line-height:160%">cmRCT: Cohort multiple randomized controlled trial</p>
      <p style="line-height:160%">CRT: Chemoradiation treatment</p>
      <p style="line-height:160%">CT: Computed tomography</p>
      <p style="line-height:160%">CTV: Clinical target volume</p>
      <p style="line-height:160%">DSMB: Data and safety monitoring board</p>
      <p style="line-height:160%">DWI: Diffusion-weighted imaging</p>
      <p style="line-height:160%">EBR: External beam radiation</p>
      <p style="line-height:160%">EORTC: European Organization for Research and Treatment of Cancer</p>
      <p style="line-height:160%">GTV: Gross tumor volume</p>
      <p style="line-height:160%">IMRT: Intensity-modulated radiotherapy</p>
      <p style="line-height:160%">LAR: Low anterior resection</p>
      <p style="line-height:160%">LARC: Locally advanced rectal cancer</p>
      <p style="line-height:160%">MRI: Magnetic resonance imaging</p>
      <p style="line-height:160%">OAR: Organ at risk</p>
      <p style="line-height:160%">pCR: Pathologic complete response, defined as Mandard grade 1 (TRG 1)</p>
      <p style="line-height:160%">PICNIC: ProspectIve data CollectioN Initiative on Colorectal cancer</p>
      <p style="line-height:160%">PROMs: Patient-reported outcome measures</p>
      <p style="line-height:160%">PTV: Planned target volume</p>
      <p style="line-height:160%">RCT: Randomized controlled trial</p>
      <p style="line-height:160%">SAE: Serious adverse event</p>
      <p style="line-height:160%">sCRT: Standard chemoradiation treatment</p>
      <p style="line-height:160%">TRG: Tumor regression grade, as defined by Mandard classification</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors declare that they have no competing interests.</p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">JPMB, HMV, MI and OR designed and coordinated the study procedures. WMUVG and MK helped
         design the study. JJEK, ME, BWR, ES and BVA designed, performed and calculated treatment
         plan parameters. All authors read and approved the final manuscript.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a>International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012:
               Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
               Accessed 14 Feb 2015.
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a>Netherlands Cancer Registry. Cancer statistics in the Netherlands. 2013. http://www.cijfersoverkanker.nl/.
               Accessed 14 Feb 2015.
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Maas M,  Nelemans PJ,  Valentini V,  Das P,  Rödel C,  Kuo LJ, <em>et al</em>.: <strong> Long-term outcome in patients with a pathological complete response after chemoradiation
                  for rectal cancer: a pooled analysis of individual patient data. </strong><p><em>Lancet Oncol.</em> 2010,  <strong>11</strong><strong>:</strong>835-44.  <a target="_blank" href="/pubmed/20692872">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20692872">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Sanghera P,  Wong DW,  McConkey CC,  Geh JI,  Hartley A: <strong> Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological
                  response. </strong><p><em>Clin Oncol (R Coll Radiol).</em> 2008,  <strong>20</strong><strong>:</strong>176-83.  <a target="_blank" href="/pubmed/18248971">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18248971">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Mandard AM,  Dalibard F,  Mandard JC,  Marnay J,  Henry-Amar M,  Petiot JF, <em>et al</em>.: <strong> Pathologic assessment of tumor regression after preoperative chemoradiotherapy of
                  esophageal carcinoma: clinicopathologic correlations. </strong><p><em>Cancer.</em> 1994,  <strong>73</strong><strong>:</strong>2680-6.  <a target="_blank" href="/pubmed/8194005">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8194005">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Burbach JP,  den Harder AM,  Intven M,  van Vulpen M,  Verkooijen HM,  Reerink O: <strong> Impact of radiotherapy boost on pathological complete response in patients with locally
                  advanced rectal cancer: a systematic review and meta-analysis. </strong><p><em>Radiother Oncol.</em> 2014,  <strong>113</strong><strong>:</strong>1-9.  <a target="_blank" href="/pubmed/25281582">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=25281582">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> Bökkerink GMJ,  de Graaf EJ,  Punt CJ,  Nagtegaal ID,  Rütten H,  Nuyttens JJ, <em>et al</em>.: <strong> The CARTS study: chemoradiation therapy for rectal cancer in the distal rectum followed
                  by organ-sparing transanal endoscopic microsurgery. </strong><p><em>BMC Surg.</em> 2011,  <strong>11</strong><strong>:</strong>34.  <a target="_blank" href="/pubmed/22171697">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1471-2482-11-34">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B7" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Pucciarelli S,  De Paoli A,  Guerrieri M,  La Torre G,  Maretto I,  De Marchi F, <em>et al</em>.: <strong> Local excision after preoperative chemoradiotherapy for rectal cancer: results of
                  a multicenter phase II clinical trial. </strong><p><em>Dis Colon Rectum.</em> 2013,  <strong>56</strong><strong>:</strong>1349-56.  <a target="_blank" href="/pubmed/24201388">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24201388">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a>ISRCTN Registry ISRCTN14422743. Transanal endoscopic microsurgery (TEM) and Radiotherapy
               in Early rectal Cancer: a randomised phase II feasibility study. http://www.controlled-trials.com/ISRCTN14422743/.
               Accessed 14 Feb 2015.
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Maas M,  Beets-Tan RG,  Lambregts DM,  Lammering G,  Nelemans PJ,  Engelen SM, <em>et al</em>.: <strong> Wait-and-see policy for clinical complete responders after chemoradiation for rectal
                  cancer. </strong><p><em>J Clin Oncol.</em> 2011,  <strong>29</strong><strong>:</strong>4633-40.  <a target="_blank" href="/pubmed/22067400">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22067400">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Smith JD,  Ruby JA,  Goodman KA,  Saltz LB,  Guillem JG,  Weiser MR, <em>et al</em>.: <strong> Nonoperative management of rectal cancer with complete clinical response after neoadjuvant
                  therapy. </strong><p><em>Ann Surg.</em> 2012,  <strong>256</strong><strong>:</strong>965-72.  <a target="_blank" href="/pubmed/23154394">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23154394">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Habr-Gama A,  Gama-Rodrigues J,  São Julião GP,  Proscurshim I,  Sabbagh C,  Lynn PB, <em>et al</em>.: <strong> Local recurrence after complete clinical response and watch and wait in rectal cancer
                  after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. </strong><p><em>Int J Radiat Oncol Biol Phys.</em> 2014,  <strong>88</strong><strong>:</strong>822-8.  <a target="_blank" href="/pubmed/24495589">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24495589">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Agarwal A,  Chang GJ,  Hu CY,  Taggart M,  Rashid A,  Park IJ, <em>et al</em>.: <strong> Quantified pathologic response assessed as residual tumor burden is a predictor of
                  recurrence-free survival in patients with rectal cancer who undergo resection after
                  neoadjuvant chemoradiotherapy. </strong><p><em>Cancer.</em> 2013,  <strong>119</strong><strong>:</strong>4231-41.  <a target="_blank" href="/pubmed/24089344">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24089344">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Martin ST,  Heneghan HM,  Winter DC: <strong> Systematic review and meta-analysis of outcomes following pathological complete response
                  to neoadjuvant chemoradiotherapy for rectal cancer. </strong><p><em>Br J Surg.</em> 2012,  <strong>99</strong><strong>:</strong>918-28.  <a target="_blank" href="/pubmed/22362002">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22362002">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Zorcolo L,  Rosman AS,  Restivo A,  Pisano M,  Nigri GR,  Fancellu A, <em>et al</em>.: <strong> Complete pathologic response after combined modality treatment for rectal cancer and
                  long-term survival: a meta-analysis. </strong><p><em>Ann Surg Oncol.</em> 2012,  <strong>19</strong><strong>:</strong>2822-32.  <a target="_blank" href="/pubmed/22434243">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22434243">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a>ClinicalTrials.gov NCT02070146. The PICNIC Project: a ProspectIve Data CollectioN
               Initiative on Colorectal Cancer. http://clinicaltrials.gov/show/NCT02070146. Accessed
               14 Feb 2015.
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Relton C,  Torgerson D,  O’Cathain A,  Nicholl J: <strong> Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple
                  randomised controlled trial” design. </strong><p><em>BMJ.</em> 2010,  <strong>340</strong><strong>:</strong>c1066.  <a target="_blank" href="/pubmed/20304934">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20304934">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Sobin LH,  Fleming ID: <strong> TNM Classification of malignant tumors. Fifth edition (1997). Union internationale
                  contre le cancer and the American joint committee on cancer. </strong><p><em>Cancer</em> 1997,  <strong>80</strong><strong>:</strong>1803-4.  <a target="_blank" href="/pubmed/9351551">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9351551">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a>Dutch National Guidelines for Oncological Care: colorectal carcinoma. Version 3.0.
               Dutch. http://www.oncoline.nl/colorectaalcarcinoom. Accessed 14 Feb 2015.
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> Roels S,  Duthoy W,  Haustermans K,  Penninckx F,  Vandecaveye V,  Boterberg T, <em>et al</em>.: <strong> Definition and delineation of the clinical target volume for rectal cancer. </strong><p><em>Int J Radiat Oncol Biol Phys.</em> 2006,  <strong>65</strong><strong>:</strong>1129-42.  <a target="_blank" href="/pubmed/16750329">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16750329">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Kapiteijn E,  Marijnen CA,  Nagtegaal ID,  Putter H,  Steup WH,  Wiggers T, <em>et al</em>.: <strong> Preoperative radiotherapy combined with total mesorectal excision for resectable rectal
                  cancer. </strong><p><em>N Engl J Med.</em> 2001,  <strong>345</strong><strong>:</strong>638-46.  <a target="_blank" href="/pubmed/11547717">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11547717">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Intven M,  Reerink O,  Philippens ME: <strong> Diffusion-weighted MRI in locally advanced rectal cancer: pathological response prediction
                  after neo-adjuvant radiochemotherapy. </strong><p><em>Strahlenther Onkol.</em> 2013,  <strong>189</strong><strong>:</strong>117-22.  <a target="_blank" href="/pubmed/23283590">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23283590">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Joiner M,  Van der Kogel A: <em>Basic clinical radiobiology</em>.  4th edition.  CRC Press, Boca Raton, FL;  2009. <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B23" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a>Kleijnen JJE, Van Asselen B, Burbach JPM, Intven M, Reerink O, Lagendijk JJW, et al.
               MRI-based inter-fraction motion analysis for rectal cancer boost radiotherapy [abstract
               OC-0574]. In Proceedings of the European Society for Radiotherapy &amp; Oncology: ESTRO
               33; 4–8 Apr 2014; Vienna, Austria.
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Quirke P,  Morris E: <strong> Reporting colorectal cancer. </strong><p><em>Histopathology.</em> 2007,  <strong>50</strong><strong>:</strong>103-12.  <a target="_blank" href="/pubmed/17204025">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17204025">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a>National Cancer Institute, National Institutes of Health. Common Terminology Criteria
               for Adverse Events (CTCAE) v.4 data files. http://evs.nci.nih.gov/ftp1/CTCAE/About.html]
               Accessed 14 Feb 2015.
            </p>
         </li>
         <li id="B27">
            <p><a name="B27"></a> Aaronson NK,  Ahmedzai S,  Bergman B,  Bullinger M,  Cull A,  Duez NJ, <em>et al</em>.: <strong> The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life
                  instrument for use in international clinical trials in oncology. </strong><p><em>J Natl Cancer Inst.</em> 1993,  <strong>85</strong><strong>:</strong>365-76.  <a target="_blank" href="/pubmed/8433390">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8433390">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B27" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B27','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B28">
            <p><a name="B28"></a> Gujral S,  Conroy T,  Fleissner C,  Sezer O,  King PM,  Avery KN, <em>et al</em>.: <strong> Assessing quality of life in patients with colorectal cancer: an update of the EORTC
                  quality of life questionnaire. </strong><p><em>Eur J Cancer.</em> 2007,  <strong>43</strong><strong>:</strong>1564-73.  <a target="_blank" href="/pubmed/17521904">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17521904">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B28" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B28','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B29">
            <p><a name="B29"></a> Whistance RN,  Conroy T,  Chie W,  Costantini A,  Sezer O,  Koller M, <em>et al</em>.: <strong> Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to
                  assess health-related quality of life in patients with colorectal cancer. </strong><p><em>Eur J Cancer.</em> 2009,  <strong>45</strong><strong>:</strong>3017-26.  <a target="_blank" href="/pubmed/19765978">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19765978">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B29" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B29','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B30">
            <p><a name="B30"></a> Appelt AL,  Ploen J,  Vogelius IR,  Bentzen SM,  Jakobsen A: <strong> Radiation dose–response model for locally advanced rectal cancer after preoperative
                  chemoradiation therapy. </strong><p><em>Int J Radiat Oncol Biol Phys.</em> 2013,  <strong>85</strong><strong>:</strong>74-80.  <a target="_blank" href="/pubmed/22763027">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22763027">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B30" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B30','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B31">
            <p><a name="B31"></a> Connell AM: <strong> Employing complier average causal effect analytic methods to examine effects of randomized
                  encouragement trials. </strong><p><em>Am J Drug Alcohol Abuse.</em> 2009,  <strong>35</strong><strong>:</strong>253-9.  <a target="_blank" href="/pubmed/20180678">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20180678">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B31" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B31','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B32">
            <p><a name="B32"></a> Osoba D,  Bezjak A,  Brundage M,  Zee B,  Tu D,  Pater J, <em>et al</em>.: <strong> Analysis and interpretation of health-related quality-of-life data from clinical trials:
                  basic approach of the National Cancer Institute of Canada Clinical Trials Group. </strong><p><em>Eur J Cancer.</em> 2005,  <strong>41</strong><strong>:</strong>280-7.  <a target="_blank" href="/pubmed/15661554">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15661554">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B32" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B32','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B33">
            <p><a name="B33"></a>ClinicalTrials.gov NCT01951521. RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation
               BOOST in Locally Advanced Rectal Cancer (RECTAL BOOST study). http://clinicaltrials.gov/show/NCT01951521.
               Accessed 13 Feb 2015.
            </p>
         </li>
         <li id="B34">
            <p><a name="B34"></a> Gerard JP,  Chapet O,  Nemoz C,  Hartweig J,  Romestaing P,  Coquard R, <em>et al</em>.: <strong> Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy:
                  the Lyon R96-02 randomized trial. </strong><p><em>J Clin Oncol.</em> 2004,  <strong>22</strong><strong>:</strong>2404-9.  <a target="_blank" href="/pubmed/15197202">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15197202">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0586-4&amp;bibl=B34" onclick="popup('/sfx_links?ui=s13063-015-0586-4&amp;bibl=B34','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/015/0586/4",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

